{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06393712",
            "orgStudyIdInfo": {
                "id": "ALN-APP-002"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-510137-29-00",
                    "type": "CTIS"
                }
            ],
            "organization": {
                "fullName": "Alnylam Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy",
            "officialTitle": "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)",
            "acronym": "cAPPricorn-1",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-phase-trial-of-aln-app-in-patients-with-cerebral-amyloid-angiopathy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-19",
            "studyFirstSubmitQcDate": "2024-04-26",
            "studyFirstPostDateStruct": {
                "date": "2024-05-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Alnylam Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months."
        },
        "conditionsModule": {
            "conditions": [
                "Cerebral Amyloid Angiopathy"
            ],
            "keywords": [
                "CAA"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ALN-APP",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be administered multiple doses of ALN-APP during the double-blind treatment period and optional open-label extension period.",
                    "interventionNames": [
                        "Drug: ALN-APP"
                    ]
                },
                {
                    "label": "Placebo/ALN-APP",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will be administered multiple doses of placebo during the double-blind treatment period. Participants who continue into the optional open-label extension period will be administered multiple doses of ALN-APP.",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: ALN-APP"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo will be administered intrathecally",
                    "armGroupLabels": [
                        "Placebo/ALN-APP"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "ALN-APP",
                    "description": "ALN-APP will be administered intrathecally",
                    "armGroupLabels": [
                        "ALN-APP",
                        "Placebo/ALN-APP"
                    ],
                    "otherNames": [
                        "mivelsiran"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Double-blind Treatment Period: Annualized Rate of New Lobar Cerebral Microbleeds (CMBs) Assessed on Magnetic Resonance Imaging (MRI) of Brain in Patients with Sporadic Cerebral Amyloid Angiopathy (sCAA)",
                    "timeFrame": "Up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Double-blind Treatment Period: Global Rank Based on Severity, Count, Symptom Burden, and Timing of New Clinical Hemorrhagic Events and Hemorrhagic Lesions Assessed on MRI of Brain",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Double-blind Treatment Period: Change from Baseline Over Time in Cerebrovascular Vasoreactivity Measured by Blood Oxygenation Level Dependent (BOLD) Parameters with Visual-evoked Functional MRI",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Double-blind Treatment Period: Incidence of New Cerebral Hemorrhagic Lesions and White Matter Hyperintensities Assessed on MRI of Brain",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Double-blind Treatment Period: Change from Baseline Over Time in the Total Cerebral Amyloid Angiopathy (CAA) Small Vessel Disease Score Assessed on MRI of Brain",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Double-blind Treatment Period: Change from Baseline in Soluble Amyloid Precursor Protein Alpha (sAPP\u03b1) Concentration in Cerebrospinal Fluid (CSF)",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Double-blind Treatment Period: Change from Baseline in Soluble Amyloid Precursor Protein Beta (sAPP\u03b2) Concentration in CSF",
                    "timeFrame": "Up to 24 months"
                },
                {
                    "measure": "Double-blind Treatment Period and Open-label Extension (OLE) Period: Frequency of Adverse Events",
                    "timeFrame": "Up to 48 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria (sporadic CAA patients):\n\n* Is 50 years or older\n* Has probable CAA per the Boston Criteria Version 2.0\n\nInclusion Criteria (Dutch-type CAA patients):\n\n* Is 30 years or older\n* Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA\n\nExclusion Criteria:\n\n* Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)\n* Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3\u00d7upper limit of normal (ULN) at Screening\n* Has estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73m\\^2 at Screening\n* Has recently received an investigational agent\n* Has had treatment with amyloid-targeting antibody\n\nNote: other protocol defined inclusion / exclusion criteria apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "30 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Alnylam Clinical Trial Information Line",
                    "role": "CONTACT",
                    "phone": "1-877-ALNYLAM",
                    "email": "clinicaltrials@alnylam.com"
                },
                {
                    "name": "Alnylam Clinical Trial Information Line",
                    "role": "CONTACT",
                    "phone": "1-877-256-9526",
                    "email": "clinicaltrials@alnylam.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Alnylam Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Plymouth",
                    "state": "Massachusetts",
                    "zip": "02360",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.95844,
                        "lon": -70.66726
                    }
                },
                {
                    "facility": "Clinical Trial Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the United States (US) and/or the European Union (EU).\n\nData will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website www.vivli.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016657",
                    "term": "Cerebral Amyloid Angiopathy"
                },
                {
                    "id": "D000028243",
                    "term": "Cerebral Amyloid Angiopathy, Familial"
                },
                {
                    "id": "D000000686",
                    "term": "Amyloidosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000057165",
                    "term": "Proteostasis Deficiencies"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000002539",
                    "term": "Cerebral Arterial Diseases"
                },
                {
                    "id": "D000020765",
                    "term": "Intracranial Arterial Diseases"
                },
                {
                    "id": "D000002561",
                    "term": "Cerebrovascular Disorders"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000020739",
                    "term": "Brain Diseases, Metabolic, Inborn"
                },
                {
                    "id": "D000001928",
                    "term": "Brain Diseases, Metabolic"
                },
                {
                    "id": "D000059345",
                    "term": "Cerebral Small Vessel Diseases"
                },
                {
                    "id": "D000028226",
                    "term": "Amyloidosis, Familial"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4021",
                    "name": "Amyloidosis",
                    "asFound": "Amyloid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19026",
                    "name": "Cerebral Amyloid Angiopathy",
                    "asFound": "Cerebral Amyloid Angiopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23333",
                    "name": "Cerebral Amyloid Angiopathy, Familial",
                    "asFound": "Cerebral Amyloid Angiopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28747",
                    "name": "Proteostasis Deficiencies",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5788",
                    "name": "Cerebral Arterial Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22521",
                    "name": "Intracranial Arterial Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5810",
                    "name": "Cerebrovascular Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5205",
                    "name": "Brain Diseases, Metabolic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22498",
                    "name": "Brain Diseases, Metabolic, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M29437",
                    "name": "Cerebral Small Vessel Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23329",
                    "name": "Amyloidosis, Familial",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T2740",
                    "name": "Hereditary Cerebral Hemorrhage With Amyloidosis",
                    "asFound": "Cerebral Amyloid Angiopathy",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}